Axon Therapies Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$32M
- Investors
-
7
Axon Therapies General Information
Description
Developer of a healthcare device designed to reduce sympathetic nerve activity and address the root cause of heart failure. The company's device allows clinicians to ablate the right greater splanchnic nerve using a small catheter inserted through the groin and helps to normalize sympathetic nervous activity, to shift blood volume from the heart back to the splanchnic bed, reducing pressures in the heart, enabling clinicians to begin treatment quickly, resulting in a high likelihood of successful treatment.
Contact Information
Website
www.axontherapies.comCorporate Office
- 345 Park Avenue South
- New York, NY 10010
- United States
Corporate Office
- 345 Park Avenue South
- New York, NY 10010
- United States
Axon Therapies Timeline
Axon Therapies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series A) | 25-Sep-2025 | $32M | Completed | Generating Revenue | ||
| 6. Debt - General | 25-Apr-2023 | Completed | Clinical Trials - General | |||
| 5. Later Stage VC (Series A) | 28-Jan-2021 | Completed | Clinical Trials - General | |||
| 4. Later Stage VC (Series A) | 07-Feb-2019 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series AA) | 26-Jun-2017 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series AA) | 19-Apr-2016 | $2M | $2M | Completed | Clinical Trials - General | |
| 1. Accelerator/Incubator | Completed | Startup |
Axon Therapies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A V | ||||||||
| Series A NV | ||||||||
| Series AA NV | 1,833,334 | $0.001000 | $0.11 | $1.8 | $1.8 | 1x | $1.8 | 15.44% |
| Series AA V | 1,650,000 | $0.001000 | $0.12 | $2 | $2 | 1x | $2 | 0% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Axon Therapies Comparisons
Industry
Financing
Details
Axon Therapies Competitors (17)
One of Axon Therapies’s 17 competitors is BioVentrix, a Venture Capital-Backed company based in Mansfield, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioVentrix | Venture Capital-Backed | Mansfield, MA | ||||
| ClearFlow | Venture Capital-Backed | Irvine, CA | ||||
| Magnolia Medical Technologies | Private Equity-Backed | Seattle, WA | ||||
| HighLife | Venture Capital-Backed | Paris, France | ||||
| Biotronik | Corporate Backed or Acquired | Berlin, Germany |
Axon Therapies Patents
Axon Therapies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026076344-A1 | A method of treating a patient having heart failure and a method of selecting a patient for a splanchnic ablation procedure | Pending | 04-Oct-2024 | ||
| US-12390220-B2 | Surgical stapler cartridge having raised surface to promote buttress adhesion | Active | 19-May-2023 | ||
| US-20240382202-A1 | Surgical stapler cartridge having raised surface to promote buttress adhesion | Active | 19-May-2023 | ||
| JP-2024520745-A | Method, device and system for treating a patient with gsn ablation | Pending | 07-Jun-2021 | ||
| AU-2022290510-A1 | Methods, devices and systems for treating a patient by gsn ablation | Pending | 07-Jun-2021 | A61B18/1492 |
Axon Therapies Signals
Axon Therapies Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CDBI Partners | Venture Capital | Minority | ||
| Earlybird Venture Capital | Venture Capital | Minority | ||
| KOFA Healthcare | Venture Capital | Minority | ||
| Santé Ventures | Venture Capital | Minority | ||
| Deerfield Management | Venture Capital | Minority |
Axon Therapies FAQs
-
When was Axon Therapies founded?
Axon Therapies was founded in 2014.
-
Where is Axon Therapies headquartered?
Axon Therapies is headquartered in New York, NY.
-
What is the size of Axon Therapies?
Axon Therapies has 20 total employees.
-
What industry is Axon Therapies in?
Axon Therapies’s primary industry is Surgical Devices.
-
Is Axon Therapies a private or public company?
Axon Therapies is a Private company.
-
What is Axon Therapies’s current revenue?
The current revenue for Axon Therapies is .
-
How much funding has Axon Therapies raised over time?
Axon Therapies has raised $75.8M.
-
Who are Axon Therapies’s investors?
CDBI Partners, Earlybird Venture Capital, KOFA Healthcare, Santé Ventures, and Deerfield Management are 5 of 7 investors who have invested in Axon Therapies.
-
Who are Axon Therapies’s competitors?
BioVentrix, ClearFlow, Magnolia Medical Technologies, HighLife, and Biotronik are some of the 17 competitors of Axon Therapies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process